



Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

March 11, 2026

Company to host conference call and webcast at 8:00 a.m. EDT

CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the fiscal year ended December 31, 2025 and provide a business update on March 18, 2026.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:

Date: Wednesday, March 18, 2026

Time: 8:00 a.m. Eastern Daylight Time (EDT)

Toll Free: 1-877-423-9813

International: 1-201-689-8573

Israeli Toll Free: 1-809-406-247

Conference ID: 13758983

Call me™ <http://bit.ly/4aQQNnE>

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details:

The conference will be webcast live from the Protalix website and will be available via the following links:

Company Link: <https://ir.protalix.com/news-events/events>

Webcast Link: <https://tinyurl.com/4jxzchdh>

Conference ID: 13758983

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact

Mike Moyer, Managing Director

LifeSci Advisors

+1-617-308-4306

mmoyer@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

 View original content: <https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2025-financial-results-and-business-update-on-march-18-2026-302710843.html>

SOURCE Protalix BioTherapeutics, Inc.